{"contentid": 488164, "importid": NaN, "name": "USA drops Lilly's biologic monotherapy for COVID-19", "introduction": "The USA has stopped distributing the antibody bamlanivimab as monotherapy to treat certain patients with COVID-19.", "content": "<p>The USA has stopped distributing the antibody bamlanivimab as monotherapy to treat certain patients with COVID-19.</p>\n<p>In a statement, the US Department of Health and Human Services (HSS) said that the move was in response to a &ldquo;sustained increase in SARS-CoV-2 viral variants in the United States that are resistant to bamlanivimab administered alone.&rdquo;</p>\n<p>In addition, the HSS said there was more availability of other authorized monoclonal antibody therapies that it believed would remain effective against these variants.</p>\n<p>Developed by Eli Lilly (NYSE: LLY), the US government has already committed to purchasing a total of 1.45 million doses of bamlanivimab alone, after the therapy was granted Emergency Use Authorization (EUA).</p>\n<p>Authorities have also placed an order for a combination of bamlanivimab and etesevimab, which has been approved as a dual therapy to treat mild to moderate disease.</p>\n<p>Distribution of Lilly&rsquo;s combination therapy is not affected by the HSS&rsquo; decision, and will continue, as will the use of Regeneron&rsquo;s (Nasdaq: REGN) antibody cocktail REGEN-COV.</p>\n<p>In Europe, a scientific panel of the European Medicines Agency (EMA) issued a positive scientific opinion for Lilly&rsquo;s combination antibody therapy, as well as the monotherapy option, in early March.</p>\n<p>The decision from the EMA could pave the way for broader access in low- and middle-income countries, where Lilly has said it could provide doses at &ldquo;greatly reduced costs or free of charge.&rdquo;</p>", "date": "2021-03-26 13:19:00", "meta_title": NaN, "meta_keywords": "monotherapy, bamlanivimab, antibody, COVID-, Lilly, treat, therapy, drops, biologic, distributing, patients, stopped, combination, statement, Department", "meta_description": "The USA has stopped distributing the antibody bamlanivimab as monotherapy to treat certain patients with COVID-19.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-26 13:18:26", "updated": "2021-03-26 14:24:28", "access": NaN, "url": "https://www.thepharmaletter.com/article/usa-drops-lilly-s-biologic-monotherapy-for-covid-19", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "lilly-logo-big.jpg", "image2id": "lilly-logo-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Anti-virals", "topic_tag": "Coronavirus, Focus On, Public health, Research", "geography_tag": "USA", "company_tag": "Eli Lilly & Company", "drug_tag": "bamlanivimab, etesevimab", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-26 13:19:00"}